Effect of prostaglandin F2α (PGF2α), indomethacin, tamoxifen or estradiol-17β on prostaglandin E (PGE), PGF2α and estradiol-17β secretion in 88 to 90-day pregnant sheep

P. J. Bridges; Y. S. Weems; L. M. Kim; B. R. Leamaster; D. L. Vincent; C. W. Weems

doi:10.1016/S0090-6980(99)00036-2

Effect of prostaglandin F₂α (PGF₂α), indomethacin, tamoxifen or estradiol-17β on prostaglandin E (PGE), PGF₂α and estradiol-17β secretion in 88 to 90-day pregnant sheep

P. J. Bridges, Y. S. Weems, L. M. Kim, B. R. Leamaster, D. L. Vincent, C. W. Weems

Animal and Food Sciences

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Treatment with PGF₂α plus estradiol-17β aborts 90-day pregnant ewes, whereas PGF₂α or estradiol-17β alone does not abort ewes. The objective of this experiment was to evaluate whether tamoxifen, an estrogen receptor antagonist, estradiol-17β, prostaglandin F₂α (PGF₂α), indomethacin, or some of their interactions affected ovine uterine/placental secretion of PGF₂α, estradiol-17β or prostaglandins E (PGE), because a single treatment with PGF₂α and estradiol-17β given every 6 h aborts 90-day pregnant ewes. Concentrations of PGF₂α in uterine venous blood were increased (P ≤ 0.05) by estradiol-17β, PGF₂α + estradiol-17β, and PGF₂α + tamoxifen, and decreased (P ≤ 0.05) by indomethacin or PGF₂α + indomethacin at 72 h when compared to the 0 h samples. Concentrations of PGE in uterine venous blood were decreased (P ≤ 0.05) by indomethacin and PGF₂α + indomethacin and increased (P ≤ 0.05) by PGF₂α + estradiol-17β at 72 h when compared to the 0 h samples. Concentrations of PGF₂α in inferior vena cava blood at 6 h were increased (P ≤ 0.05) by PGF₂α either alone or in combination with indomethacin, tamoxifen, or estradiol-17β, which is due to the PGF₂α injected. Concentrations of PGF₂α in inferior vena cava blood in PGF₂α + estradiol-17β-treated 88- to 90-day pregnant ewes increased (P ≤ 0.05) linearly over the 72-h sampling period and averaged 4.0 + 0.4 ng/ml. Concentrations of PGF₂α in inferior vena cava blood of control, PGF₂α, tamoxifen, PGF₂α + indomethacin, PGF₂α + tamoxifen, and estradiol-17β- treated ewes did not differ (P ≥ 0.05) and averaged 0.4 + 0.04 ng/ml. Profiles of PGE in inferior vena cava blood of 88- to 90-day pregnant ewes treated with vehicle, PGF₂α, estradiol-17β, tamoxifen, tamoxifen + PGF₂α, or estradiol-17β + PGF₂α did not differ (P ≥ 0.05). Concentrations of PGE in inferior vena cava blood of 88- to 90-day pregnant ewes treated with indomethacin or PGF₂α + indomethacin were lower (P ≤ 0.05) than in control ewes. Concentrations of estradiol-17β in jugular venous plasma of PGF₂α + estradiol-17β-treated 88- to 90-day pregnant ewes increased linearly and differed (P ≤ 0.05) from controls. Profiles of estradiol-17β in jugular venous plasma of PGF₂α, indomethacin, tamoxifen, and PGF₂α + tamoxifen and PGF₂α + indomethacin, estradiol-17β, and controls did not differ (P ≥ 0.05). It is concluded that treatment with a single injection of PGF₂α and estradiol-17β given every 6 h causes a linear increase in PGF₂α and estradiol-17β.

Original language	English
Pages (from-to)	167-178
Number of pages	12
Journal	Prostaglandins and Other Lipid Mediators
Volume	58
Issue number	2-4
DOIs	https://doi.org/10.1016/S0090-6980(99)00036-2
State	Published - Oct 1999

Bibliographical note

Funding Information:
☆ This research was supported in part by United States Department of Agriculture Cooperative State Research, Education and Extension Services (USDA CSREES) Special Grant No. 95-34135-1776 to C.W. Weems and managed by the Pacific Basin Advisory Group and Hawaii Hatch Project 259 as its contribution to USDA W–112 Regional Research Project.

Keywords

Estradiol-17β
Indomethacin
PGE
PGFα
Pregnancy
Sheep
Tamoxifen

ASJC Scopus subject areas

Biochemistry
Physiology
Pharmacology
Cell Biology

Access to Document

10.1016/S0090-6980(99)00036-2

Cite this

Bridges, P. J., Weems, Y. S., Kim, L. M., Leamaster, B. R., Vincent, D. L., & Weems, C. W. (1999). Effect of prostaglandin F₂α (PGF₂α), indomethacin, tamoxifen or estradiol-17β on prostaglandin E (PGE), PGF₂α and estradiol-17β secretion in 88 to 90-day pregnant sheep. Prostaglandins and Other Lipid Mediators, 58(2-4), 167-178. https://doi.org/10.1016/S0090-6980(99)00036-2

@article{e31e9fd5e30a45499df9e8515162402d,

title = "Effect of prostaglandin F2α (PGF2α), indomethacin, tamoxifen or estradiol-17β on prostaglandin E (PGE), PGF2α and estradiol-17β secretion in 88 to 90-day pregnant sheep",

abstract = "Treatment with PGF2α plus estradiol-17β aborts 90-day pregnant ewes, whereas PGF2α or estradiol-17β alone does not abort ewes. The objective of this experiment was to evaluate whether tamoxifen, an estrogen receptor antagonist, estradiol-17β, prostaglandin F2α (PGF2α), indomethacin, or some of their interactions affected ovine uterine/placental secretion of PGF2α, estradiol-17β or prostaglandins E (PGE), because a single treatment with PGF2α and estradiol-17β given every 6 h aborts 90-day pregnant ewes. Concentrations of PGF2α in uterine venous blood were increased (P ≤ 0.05) by estradiol-17β, PGF2α + estradiol-17β, and PGF2α + tamoxifen, and decreased (P ≤ 0.05) by indomethacin or PGF2α + indomethacin at 72 h when compared to the 0 h samples. Concentrations of PGE in uterine venous blood were decreased (P ≤ 0.05) by indomethacin and PGF2α + indomethacin and increased (P ≤ 0.05) by PGF2α + estradiol-17β at 72 h when compared to the 0 h samples. Concentrations of PGF2α in inferior vena cava blood at 6 h were increased (P ≤ 0.05) by PGF2α either alone or in combination with indomethacin, tamoxifen, or estradiol-17β, which is due to the PGF2α injected. Concentrations of PGF2α in inferior vena cava blood in PGF2α + estradiol-17β-treated 88- to 90-day pregnant ewes increased (P ≤ 0.05) linearly over the 72-h sampling period and averaged 4.0 + 0.4 ng/ml. Concentrations of PGF2α in inferior vena cava blood of control, PGF2α, tamoxifen, PGF2α + indomethacin, PGF2α + tamoxifen, and estradiol-17β- treated ewes did not differ (P ≥ 0.05) and averaged 0.4 + 0.04 ng/ml. Profiles of PGE in inferior vena cava blood of 88- to 90-day pregnant ewes treated with vehicle, PGF2α, estradiol-17β, tamoxifen, tamoxifen + PGF2α, or estradiol-17β + PGF2α did not differ (P ≥ 0.05). Concentrations of PGE in inferior vena cava blood of 88- to 90-day pregnant ewes treated with indomethacin or PGF2α + indomethacin were lower (P ≤ 0.05) than in control ewes. Concentrations of estradiol-17β in jugular venous plasma of PGF2α + estradiol-17β-treated 88- to 90-day pregnant ewes increased linearly and differed (P ≤ 0.05) from controls. Profiles of estradiol-17β in jugular venous plasma of PGF2α, indomethacin, tamoxifen, and PGF2α + tamoxifen and PGF2α + indomethacin, estradiol-17β, and controls did not differ (P ≥ 0.05). It is concluded that treatment with a single injection of PGF2α and estradiol-17β given every 6 h causes a linear increase in PGF2α and estradiol-17β.",

keywords = "Estradiol-17β, Indomethacin, PGE, PGFα, Pregnancy, Sheep, Tamoxifen",

author = "Bridges, {P. J.} and Weems, {Y. S.} and Kim, {L. M.} and Leamaster, {B. R.} and Vincent, {D. L.} and Weems, {C. W.}",

note = "Funding Information: ☆ This research was supported in part by United States Department of Agriculture Cooperative State Research, Education and Extension Services (USDA CSREES) Special Grant No. 95-34135-1776 to C.W. Weems and managed by the Pacific Basin Advisory Group and Hawaii Hatch Project 259 as its contribution to USDA W–112 Regional Research Project. ",

year = "1999",

month = oct,

doi = "10.1016/S0090-6980(99)00036-2",

language = "English",

volume = "58",

pages = "167--178",

number = "2-4",

}

Bridges, PJ, Weems, YS, Kim, LM, Leamaster, BR, Vincent, DL & Weems, CW 1999, 'Effect of prostaglandin F₂α (PGF₂α), indomethacin, tamoxifen or estradiol-17β on prostaglandin E (PGE), PGF₂α and estradiol-17β secretion in 88 to 90-day pregnant sheep', Prostaglandins and Other Lipid Mediators, vol. 58, no. 2-4, pp. 167-178. https://doi.org/10.1016/S0090-6980(99)00036-2

Effect of prostaglandin F₂α (PGF₂α), indomethacin, tamoxifen or estradiol-17β on prostaglandin E (PGE), PGF₂α and estradiol-17β secretion in 88 to 90-day pregnant sheep. / Bridges, P. J.; Weems, Y. S.; Kim, L. M. et al.
In: Prostaglandins and Other Lipid Mediators, Vol. 58, No. 2-4, 10.1999, p. 167-178.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effect of prostaglandin F2α (PGF2α), indomethacin, tamoxifen or estradiol-17β on prostaglandin E (PGE), PGF2α and estradiol-17β secretion in 88 to 90-day pregnant sheep

AU - Bridges, P. J.

AU - Weems, Y. S.

AU - Kim, L. M.

AU - Leamaster, B. R.

AU - Vincent, D. L.

AU - Weems, C. W.

N1 - Funding Information: ☆ This research was supported in part by United States Department of Agriculture Cooperative State Research, Education and Extension Services (USDA CSREES) Special Grant No. 95-34135-1776 to C.W. Weems and managed by the Pacific Basin Advisory Group and Hawaii Hatch Project 259 as its contribution to USDA W–112 Regional Research Project.

PY - 1999/10

Y1 - 1999/10

N2 - Treatment with PGF2α plus estradiol-17β aborts 90-day pregnant ewes, whereas PGF2α or estradiol-17β alone does not abort ewes. The objective of this experiment was to evaluate whether tamoxifen, an estrogen receptor antagonist, estradiol-17β, prostaglandin F2α (PGF2α), indomethacin, or some of their interactions affected ovine uterine/placental secretion of PGF2α, estradiol-17β or prostaglandins E (PGE), because a single treatment with PGF2α and estradiol-17β given every 6 h aborts 90-day pregnant ewes. Concentrations of PGF2α in uterine venous blood were increased (P ≤ 0.05) by estradiol-17β, PGF2α + estradiol-17β, and PGF2α + tamoxifen, and decreased (P ≤ 0.05) by indomethacin or PGF2α + indomethacin at 72 h when compared to the 0 h samples. Concentrations of PGE in uterine venous blood were decreased (P ≤ 0.05) by indomethacin and PGF2α + indomethacin and increased (P ≤ 0.05) by PGF2α + estradiol-17β at 72 h when compared to the 0 h samples. Concentrations of PGF2α in inferior vena cava blood at 6 h were increased (P ≤ 0.05) by PGF2α either alone or in combination with indomethacin, tamoxifen, or estradiol-17β, which is due to the PGF2α injected. Concentrations of PGF2α in inferior vena cava blood in PGF2α + estradiol-17β-treated 88- to 90-day pregnant ewes increased (P ≤ 0.05) linearly over the 72-h sampling period and averaged 4.0 + 0.4 ng/ml. Concentrations of PGF2α in inferior vena cava blood of control, PGF2α, tamoxifen, PGF2α + indomethacin, PGF2α + tamoxifen, and estradiol-17β- treated ewes did not differ (P ≥ 0.05) and averaged 0.4 + 0.04 ng/ml. Profiles of PGE in inferior vena cava blood of 88- to 90-day pregnant ewes treated with vehicle, PGF2α, estradiol-17β, tamoxifen, tamoxifen + PGF2α, or estradiol-17β + PGF2α did not differ (P ≥ 0.05). Concentrations of PGE in inferior vena cava blood of 88- to 90-day pregnant ewes treated with indomethacin or PGF2α + indomethacin were lower (P ≤ 0.05) than in control ewes. Concentrations of estradiol-17β in jugular venous plasma of PGF2α + estradiol-17β-treated 88- to 90-day pregnant ewes increased linearly and differed (P ≤ 0.05) from controls. Profiles of estradiol-17β in jugular venous plasma of PGF2α, indomethacin, tamoxifen, and PGF2α + tamoxifen and PGF2α + indomethacin, estradiol-17β, and controls did not differ (P ≥ 0.05). It is concluded that treatment with a single injection of PGF2α and estradiol-17β given every 6 h causes a linear increase in PGF2α and estradiol-17β.

AB - Treatment with PGF2α plus estradiol-17β aborts 90-day pregnant ewes, whereas PGF2α or estradiol-17β alone does not abort ewes. The objective of this experiment was to evaluate whether tamoxifen, an estrogen receptor antagonist, estradiol-17β, prostaglandin F2α (PGF2α), indomethacin, or some of their interactions affected ovine uterine/placental secretion of PGF2α, estradiol-17β or prostaglandins E (PGE), because a single treatment with PGF2α and estradiol-17β given every 6 h aborts 90-day pregnant ewes. Concentrations of PGF2α in uterine venous blood were increased (P ≤ 0.05) by estradiol-17β, PGF2α + estradiol-17β, and PGF2α + tamoxifen, and decreased (P ≤ 0.05) by indomethacin or PGF2α + indomethacin at 72 h when compared to the 0 h samples. Concentrations of PGE in uterine venous blood were decreased (P ≤ 0.05) by indomethacin and PGF2α + indomethacin and increased (P ≤ 0.05) by PGF2α + estradiol-17β at 72 h when compared to the 0 h samples. Concentrations of PGF2α in inferior vena cava blood at 6 h were increased (P ≤ 0.05) by PGF2α either alone or in combination with indomethacin, tamoxifen, or estradiol-17β, which is due to the PGF2α injected. Concentrations of PGF2α in inferior vena cava blood in PGF2α + estradiol-17β-treated 88- to 90-day pregnant ewes increased (P ≤ 0.05) linearly over the 72-h sampling period and averaged 4.0 + 0.4 ng/ml. Concentrations of PGF2α in inferior vena cava blood of control, PGF2α, tamoxifen, PGF2α + indomethacin, PGF2α + tamoxifen, and estradiol-17β- treated ewes did not differ (P ≥ 0.05) and averaged 0.4 + 0.04 ng/ml. Profiles of PGE in inferior vena cava blood of 88- to 90-day pregnant ewes treated with vehicle, PGF2α, estradiol-17β, tamoxifen, tamoxifen + PGF2α, or estradiol-17β + PGF2α did not differ (P ≥ 0.05). Concentrations of PGE in inferior vena cava blood of 88- to 90-day pregnant ewes treated with indomethacin or PGF2α + indomethacin were lower (P ≤ 0.05) than in control ewes. Concentrations of estradiol-17β in jugular venous plasma of PGF2α + estradiol-17β-treated 88- to 90-day pregnant ewes increased linearly and differed (P ≤ 0.05) from controls. Profiles of estradiol-17β in jugular venous plasma of PGF2α, indomethacin, tamoxifen, and PGF2α + tamoxifen and PGF2α + indomethacin, estradiol-17β, and controls did not differ (P ≥ 0.05). It is concluded that treatment with a single injection of PGF2α and estradiol-17β given every 6 h causes a linear increase in PGF2α and estradiol-17β.

KW - Estradiol-17β

KW - Indomethacin

KW - PGE

KW - PGFα

KW - Pregnancy

KW - Sheep

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0032589665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032589665&partnerID=8YFLogxK

U2 - 10.1016/S0090-6980(99)00036-2

DO - 10.1016/S0090-6980(99)00036-2

M3 - Article

C2 - 10560619

AN - SCOPUS:0032589665

SN - 0090-6980

VL - 58

SP - 167

EP - 178

JO - Prostaglandins and Other Lipid Mediators

JF - Prostaglandins and Other Lipid Mediators

IS - 2-4

ER -